Combination of urinary lipoarabinomannan assay and GeneXpert MTB/RIF ultra enhances tuberculosis detection among HIV-infected individuals
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20252828Keywords:
Tuberculosis, Lipoarabinomannan, Diagnosis, GeneXpert, KenyaAbstract
Background: Tuberculosis (TB) is a major health concern, responsible for about 10 million morbidities and 1.3 million global deaths, of which 300,000 are HIV co-infected. Timely diagnosis and treatment of TB have saved millions of lives. Lipoarabinomannan (LAM) assays and GeneXpert MTB/RIF Ultra have greatly altered TB diagnosis, but information on their performance in terms of accuracy, efficiency and turnaround time is limited. This analytic cross-sectional study investigated the diagnostic accuracy of urinary LAM and GeneXpert MTB/RIF Ultra in TB detection among adult HIV-positive individuals receiving care at Kisii Teaching and Referral Hospital.
Methods: Participants (n=372) were enrolled from facility Xpert testing log, where all patients with Xpert-positive results were recruited.
Results: There was variation in sensitivity between AlereLAM (10.8%), FujiLAM (53.2%), and EclLAM (66.7%), and generally high specificities: AlereLAM (92.3%), FujiLAM (98.9%), and EclLAM (98.1%). GeneXpert MTB/RIF Ultra had a 90.5% sensitivity and 98.1% specificity, without significant difference in sensitivity or specificity by previous TB history, hospitalization, or HIV status. Xpert and GeneXpert MTB/RIF Ultra results were concordant, with the latter showing a small reduction in specificity (difference 1.9; p=0.01). Considering trace results as positive for all cases increased sensitivity by 2.1% (p=0.01) without reduction in specificity (p=0.08).
Conclusions: FujiLAM and GeneXpert MTB/RIF Ultra have the capacity to improve TB diagnosis, especially in HIV-positive individuals and in high-burden settings, with enhanced sensitivity and specificity. Integrating these assays can boost prompt treatment initiation and better patient outcomes, although further research is needed.
Metrics
References
WHO. Tuberculosis- Key facts. 2018. Available at: www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed on 20 September 2024.
Asare, KK, Azumah DE, Adu-Gyamfi CO, Opoku YK, Adela EM, Afful P, et al. Comparison of microscopic and Xpert MTB diagnoses of presumptive mycobacteria tuberculosis infection: retrospective analysis of routine diagnosis at Cape Coast Teaching Hospital. BMC Infect Dis. 2024;24(1):660. DOI: https://doi.org/10.1186/s12879-024-09566-9
Abebaw Y, Abebe M, Tola HH, Mehammed Z, Getahun M, Gamtesa DF, et al. Pulmonary tuberculosis case notification and burden of drug resistance among children under 15 years of age in Ethiopia: sub-analysis from third-round drug resistance tuberculosis survey. BMC Pediatr, 2023;23(1):418. DOI: https://doi.org/10.1186/s12887-023-04240-6
WHO, Global tuberculosis report 2023. 2023, WHO: Geneva.
Ahsberg J, Tersbol BP, Puplampu P, Kwashie A, Commey JO, Adusi-Poku Y, et al. Use of the urine Determine LAM test in the context of tuberculosis diagnosis among inpatients with HIV in Ghana: a mixed methods study. Front Public Health. 2023;11:1271763. DOI: https://doi.org/10.3389/fpubh.2023.1271763
Click ES, Song R, Smith JP, Mchembere W, Fajans M, Hariri P, et al. Performance of Xpert MTB/RIF and mycobacterial culture on multiple specimen types for diagnosis of tuberculosis disease in young children and clinical characterization according to standardized research case definitions. The Pediatric infectious disease journal. 2022;41(8):671-7. DOI: https://doi.org/10.1097/INF.0000000000003582
Ocheretina O, Byrt E, Mabou MM, Royal-Mardi G, Merveille YM, Rouzier V, et al. False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. Diagnostic Microbiology and Infectious Disease. 2016;85(1):53-5. DOI: https://doi.org/10.1016/j.diagmicrobio.2016.01.009
Sossen B, Ryan A, Bielawski J, Greyling R, Matthews G, Hurribunce-James S, et al. Urine lipoarabinomannan for rapid tuberculosis diagnosis in HIV-infected adult outpatients in Khayelitsha. South African Journal of HIV Medicine. 2021;22(1):1226. DOI: https://doi.org/10.4102/sajhivmed.v22i1.1226
Pouzol S, Khaja Mafij Uddin M, Islam A, Jabin MS, Nigou J, Banu S, et al. Combination of exhaled breath condensate samples with lipoarabinomannan point of care assay for pulmonary tuberculosis (TB) diagnosis: protocol for a diagnostic accuracy study. BMJ Open. 2024;14(9):e087026. DOI: https://doi.org/10.1136/bmjopen-2024-087026
Broger T, Nicol MP, Sigal GB, Gotuzzo E, Zimmer AJ, Surtie S, et al. Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. Journal of Clinical Investigation. 2020;130(11):5756-64. DOI: https://doi.org/10.1172/JCI140461
Ejeta E, Beyene G, Bonsa Z, Abebe G. Xpert MTB/RIF assay for the diagnosis of Mycobacterium tuberculosis and rifampicin resistance in high Human Immunodeficiency Virus setting in Gambella regional state, southwest Ethiopia. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2018;12:14-20. DOI: https://doi.org/10.1016/j.jctube.2018.06.002
Esmail A, Tomasicchio M, Meldau R, Makambwa E, Dheda K. Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemic setting. International Journal of Infectious Diseases. 2020;95:246-52. DOI: https://doi.org/10.1016/j.ijid.2020.03.025
Zhang TH, Ma ZC, Liu RM, Shang YY, Ma LP, Han M, et al. [Evaluation of the efficacy of urine-based lipoarabinomannan antigen test in the diagnosis of pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2024;47(2):132-6.
Zhang P, Liu H, Wang H, Wu Y, Sun L, Rao M, et al. Performance of Xpert MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis using bronchoalveolar lavage samples in people living with HIV/AIDS (PLWHA) in China: a prospective study. HIV/AIDS (Auckland). 2021;13:905-16. DOI: https://doi.org/10.2147/HIV.S319117
Szekely R, Sossen B, Mukoka M, Muyoyeta M, Nakabugo E, Hella J, et al. Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability. PLoS One. 2024;19(5):e0303846. DOI: https://doi.org/10.1371/journal.pone.0303846
Sorsa A, Jerene D, Negash S, Habtamu A. Use of Xpert contributes to accurate diagnosis, timely initiation, and rational use of anti-TB treatment among childhood tuberculosis cases in South Central Ethiopia. Pediatric Health, Medicine and Therapeutics. 2020;11:153-60. DOI: https://doi.org/10.2147/PHMT.S244154
Gupta-Wright A, Peters JA, Flach C, Lawn SD. Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Medicine. 2016;14:53. DOI: https://doi.org/10.1186/s12916-016-0603-9
Simieneh A, Tadesse M, Kebede W, Gashaw M, Abebe G. Combination of Xpert MTB/RIF and Determine TB-LAM Ag improves the diagnosis of extrapulmonary tuberculosis at Jimma University Medical Center, Oromia, Ethiopia. PLoS One. 2022;17(2):e0263172. DOI: https://doi.org/10.1371/journal.pone.0263172
Hassan S, Mustafa T, Muller W, Torres L, Marijani M, Ngadaya E, et al. Comparing the cost-effectiveness of the MPT64-antigen detection test to Xpert MTB/RIF and ZN-microscopy for the diagnosis of extrapulmonary tuberculosis: an economic evaluation modelling study. PLOS Global Public Health. 2024;4(8):e0003414. DOI: https://doi.org/10.1371/journal.pgph.0003414
Srilohasin P, Warit S, Prammananan T, Smithtikarn S, Kanitpun R, Kaewparuehaschai M, et al. Advancing tuberculosis diagnosis and management in cynomolgus macaques using Xpert MTB/RIF ultra assay. Scientific Reports. 2024;14(1):1518. DOI: https://doi.org/10.1038/s41598-024-51824-y
Burke RM, Nyirenda SK, Mtenga T, Twabi HH, Joekes E, Walker NF, et al. Enhanced tuberculosis diagnosis with computer-aided chest X-ray and urine LAM in adults with HIV admitted to hospital (CASTLE study): a cluster randomised trial. Clinical Infectious Diseases. 2024. DOI: https://doi.org/10.1093/cid/ciae273
Gupta A, Kumar A, Ashraf AA, Madigubba H, Chawla K. A pilot study to evaluate urine LAM assay for diagnosis of pulmonary tuberculosis among non-HIV patients. Tropical Doctor. 2020;50(4):343-6. DOI: https://doi.org/10.1177/0049475520936164
Gao M, Wu Q, Wang X, Sun X, Li M, Bai G. Advancements in LAM-based diagnostic kit for tuberculosis detection: enhancing TB diagnosis in HIV-negative individuals. Frontiers in Microbiology. 2024;15:1367092. DOI: https://doi.org/10.3389/fmicb.2024.1367092
Bjerrum S, Ahsberg J, Szekely R, Opintan J, Lartey M, Shah M, et al. Diagnostic accuracy of urine lipoarabinomannan testing in early morning urine versus spot urine for diagnosis of tuberculosis among people with HIV. Microbiology Spectrum. 2022;10(2):e0020822. DOI: https://doi.org/10.1128/spectrum.00208-22
Zhang M, Xue M, He JQ. Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. International Journal of Infectious Diseases. 2020;90:35-45. DOI: https://doi.org/10.1016/j.ijid.2019.09.016
Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respiratory Medicine. 2020;8(4):368-82. DOI: https://doi.org/10.1016/S2213-2600(19)30370-4
Minnies S, Reeve BWP, Rockman L, Nyawo G, Naidoo CC, Kitchin N, et al. Xpert MTB/RIF Ultra is highly sensitive for the diagnosis of tuberculosis lymphadenitis in a high-HIV setting. Journal of Clinical Microbiology. 2021;59(12):e0131621. DOI: https://doi.org/10.1128/JCM.01316-21
Sun L, Zhu Y, Fang M, Shi Y, Peng X, Liao Q, et al. Evaluation of Xpert MTB/RIF Ultra assay for diagnosis of childhood tuberculosis: a multicenter accuracy study. Journal of Clinical Microbiology. 2020;58(9). DOI: https://doi.org/10.1128/JCM.00702-20
Wang G, Huang M, Jing H, Jia J, Dong L, Zhao L, et al. The practical value of Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in a high tuberculosis burden setting: a prospective multicenter diagnostic accuracy study. Microbiology Spectrum. 2022;10(4):e0094922. DOI: https://doi.org/10.1128/spectrum.00949-22
Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases. 2018;18(1):76-84. DOI: https://doi.org/10.1016/S1473-3099(17)30691-6
Dubale M, Tadesse M, Berhane M, Mekonnen M, Abebe G. Stool-based Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children at a teaching and referral hospital in Southwest Ethiopia. PLoS One. 2022;17(5):e0267661. DOI: https://doi.org/10.1371/journal.pone.0267661
Wang Y, Tan J, Lei L, Yuan Y, Li W, Zhao Y, et al. The value of Xpert MTB/RIF assay of urine samples in the early diagnosis of smear-negative urinary tuberculosis. European Journal of Medical Research. 2022;27(1):300. DOI: https://doi.org/10.1186/s40001-022-00947-x
Aurilio RB, Ferreira S, Parente A, Sant'Anna MFP, Pereira CS, Malaquias T, et al. Gene-Xpert Ultra for the diagnosis of extrapulmonary tuberculosis in children and adolescents. Revista do Instituto de Medicina Tropical de São Paulo. 2022;64:e12. DOI: https://doi.org/10.1590/s1678-9946202264012
Kamra E, Prasad T, Rais A, Dahiya B, Sheoran A, Soni A, et al. Diagnosis of genitourinary tuberculosis: detection of mycobacterial lipoarabinomannan and MPT-64 biomarkers within urine extracellular vesicles by nano-based immuno-PCR assay. Scientific Reports. 2023;13(1):11560. DOI: https://doi.org/10.1038/s41598-023-38740-3
Downloads
Published
How to Cite
Issue
Section
